Last updated: July 24, 2026
Key Takeaways for Dental Practice Sellers
- The 2026 dental market can favor sellers who understand how to use strong buyer demand from private equity-backed DSOs and traditional doctor-to-doctor exits.
- Valuation methods vary by buyer type, such as percentage of collections, SDE, or EBITDA, and using the wrong method can significantly undervalue a practice.
- A structured bidding process with multiple qualified buyers can increase final sale values by 30% to 50% compared with single-offer situations.
- Broker fee structures and valuation quality differ widely; CPA-led, diligence-grade valuations can reduce post-LOI renegotiation and improve close rates.
- McLerran & Associates offers sell-side-only representation with a high transaction rate and a long track record of guiding practice owners through both exit paths. Request a confidential evaluation of your exit options.
Two Main Paths to Sell a Dental Practice
For most of dental history, selling a practice meant finding another dentist to buy it. That path still exists and still works well for many owners. Over the last decade, however, private equity-backed Dental Service Organizations (DSOs), which manage the business side of practices while affiliated dentists retain clinical control, created a second, structurally different exit: the affiliation.
The two paths differ in valuation method, deal timeline, post-close obligations, and the type of buyer across the table. Individual buyer transactions generally close in 60 to 120 days, while DSO transactions often require 3 to 6 months because of more complex legal structures and corporate due diligence. After closing, a DSO deal typically requires a multi-year employment commitment. A doctor-to-doctor sale usually involves only a short transition period of weeks.
The information gap between these two worlds can be the central problem for sellers. A practice owner sells once in a career. A DSO negotiates acquisitions every week. Without specialized sell-side representation, where the advisor’s only client is the selling dentist, owners often negotiate from a serious disadvantage, sometimes without realizing it.
How Much Is a Dental Practice Worth to Sell?
Buyer type often drives valuation methodology. Three primary approaches are common in 2026, and using the wrong one for a given buyer can anchor price expectations far below market.
Percentage of collections, which is annual gross revenue collected from patients, remains a common shorthand for doctor-to-doctor transactions. Private sales of general dental practices in 2026 typically use collections-based valuation at 65% to 85% of annual gross collections, adjusted for overhead, owner dependence, technology, location, and growth trends.
Seller’s Discretionary Earnings (SDE), which is net income plus the owner’s total compensation, interest, depreciation, amortization, and one-time add-backs, is often used for smaller practices where the owner is the primary producer. It captures the total economic benefit flowing to a working owner-operator.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is the standard for DSO and private equity buyers. It measures the practice’s operating profitability after replacing the owner’s compensation with a market-rate associate salary, typically 28% to 32% of the doctor’s production. Single-location practices commonly trade at 5x to 8x normalized EBITDA with institutional buyers, while larger multi-location platforms can reach 8x to 12x EBITDA.
The same practice can produce very different valuations depending on buyer type. DSO buyers can sometimes pay a premium over private buyers because of differences in pricing methods and access to capital. Specialty practices can command higher multiples than general dentistry, although the specific range can depend on practice size, geography, and buyer demand.
The single largest discount factor across all methodologies is owner dependence. Practices where the selling doctor produces most of the clinical revenue can receive significant valuation discounts because buyers see more transition risk. This makes the quality of the initial valuation analysis critical. A CPA-led EBITDA analysis, such as the one McLerran & Associates builds for every engagement, unpacks every discretionary and non-recurring expense up front. That work helps the number hold when buyers review it during due diligence instead of being renegotiated downward.
Creating Real Competition Among Buyers
A single offer does not represent a market. It reflects one buyer’s opening position, set without competitive pressure and without any requirement to match what the practice could bring elsewhere.
A structured, auction-style process can change that dynamic. McLerran & Associates typically runs a 45 to 60-day bid process that generates around 10 offers from a vetted pool of qualified buyers. Dental practices taken to market through a structured multi-buyer solicitation process achieve final sale values averaging 50% above initial unsolicited offers. McLerran clients often see about a 30% increase in valuation compared with selling alone.
The spread between best-tier and middle-tier DSO acquisition offers for dental practices has never been wider. The difference between a one-bidder process and a ten-bidder process can be measured in hundreds of thousands or even millions of dollars, not just a small premium.
What Dental Brokers Typically Charge
Fee structures can vary widely across broker categories, and a firm’s model can reveal a great deal about its incentives.
Sell-side dental practice brokers typically charge sellers a commission of 8% to 12% of the sale price, with larger practices sometimes negotiating rates down to 6% to 8%. Tiered structures, such as a higher percentage on the first million of transaction value and a lower percentage on amounts above that level, are common in the lower-middle market. Most sell-side brokers in this segment charge an all-in success fee of roughly 6% to 12% of final deal value, payable only when the transaction closes.
The more important distinction often lies between paid, diligence-grade valuations and free lead-generation models. A “free” valuation is usually a quick estimate designed to attract listings, not to withstand buyer scrutiny. When that number is tested in due diligence, it can collapse, and the deal can be re-traded downward. McLerran & Associates charges for its CPA-led valuation work because that investment can make the number more defensible and the deal more likely to close. The firm focuses on selling practices, not simply listing them.
Choosing a Buyer That Fits Your Practice
Not every buyer with capital is a good buyer. DSO quality can vary widely, and provider risk, clinical continuity, declining financial performance, and reimbursement exposure can be some of the main factors DSOs walk away from potential deals. The same factors that make a DSO walk away from a weak practice can make a poorly run DSO a risky partner for a strong one.
In a DSO affiliation, the selling doctor often wears three hats at once: seller, partner, and investor. DSO transactions typically deliver 60% to 80% of total consideration as cash at closing, with the remaining 20% to 40% structured as earnouts tied to performance targets plus equity rollover in the DSO platform. That equity stake, which can represent up to 40% of total deal value, means the owner is effectively buying stock in the DSO. Vetting that investment usually involves examining the DSO’s profitability, revenue growth, management depth, and the track record of its private equity backer.
McLerran & Associates blacklists DSOs known for poor post-close environments, so they never reach the table. For buyers that do qualify, multi-year, multi-structure financial forecasting lets owners compare real after-tax proceeds across cash, equity, and earnout scenarios over 3, 5, 7, and 10-year horizons. This approach helps owners look beyond headline numbers to what they are likely to keep.
Is It Hard to Sell a Dental Practice?
A dental practice sale can be fragile. It can collapse during due diligence, financing, lease assignment, or because the valuation does not hold up when a buyer examines the details. A competitive market process that solicits indications of interest from multiple DSOs and qualified private buyers in parallel can improve transaction outcomes and pricing, while single-bidder processes often underprice the practice.
Close-rate data highlights the stakes. Do-it-yourself sales close at roughly 15% to 20%. The industry norm for brokered transactions sits around 35% to 40%. McLerran & Associates reports a transaction rate of approximately 85% to 90%, which reflects the difference between listing a practice and actually selling it. That outcome can be driven by diligence-grade valuations that do not get re-traded, a competitive process that maintains buyer urgency, and hands-on advocacy through every stage of the transaction.
See what a well-run process looks like for your practice. McLerran & Associates offers a free, confidential consultation to walk you through the approach.
How to Judge Buyer Quality
Buyer quality can be evaluated across four main dimensions: profitability, growth, leadership, and financial backing. A DSO that is not profitable at the practice level, or whose revenue growth has stalled at offices it already owns, can be a poor home for retained equity. A private equity backer that has never successfully recapitalized a dental platform can introduce meaningful risk to the equity portion of the deal.
A higher headline enterprise value can produce a weaker seller outcome than a lower offer if the structure includes more rollover equity, larger holdbacks, tighter working-capital targets, uncertain financing, or employment terms that conflict with the seller’s goals. Comparing offers usually requires modeling each one across its full structure and time horizon, not just reading the top-line number.
Quality-of-earnings defense, which means protecting the EBITDA figure agreed at the letter of intent stage when the buyer’s diligence team tries to revise it downward, is where many deals quietly lose value. McLerran & Associates defends its valuations through closing and reminds buyers that other vetted bidders remain available if agreed terms are challenged without cause.
Maximize Your Outcome With the Right Advisor
McLerran & Associates is a dental-specific, sell-side-only M&A advisory firm with approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, and more than 10,000 practices evaluated. The firm’s close rate, which is more than double the industry average, reflects its focus on defensible valuations and competitive processes. Its work splits almost evenly between doctor-to-doctor transactions and DSO affiliations, which allows owners to see a genuine side-by-side comparison before choosing a direction.
Regional offices serve clients nationally: Cleveland (Justin Klingshim), Atlanta (Matt Sutton), Northern Virginia (Andrew Kobylski), Los Angeles (Steven Au), and Phoenix (Brian Carroll, covering the Mountain West). The team brings more than 100 years of collective dental-industry experience as former investment bankers, practice-finance lenders, DSO buyers, CPAs, and advisors.
The following table illustrates how McLerran & Associates’ approach differs from other broker categories across factors that can most affect transaction outcomes.
Comparison Table: Broker Categories vs. McLerran & Associates
| Dimension | DIY / FSBO | Local Generalist Broker | Multi-Vertical Advisor | McLerran & Associates |
|---|---|---|---|---|
| Dental specialization | None | Local only, limited depth | Spread across healthcare verticals | Dental-only, national, narrow and deep |
| Both sale paths | No | Usually one path | Sometimes | Both private-buyer and DSO, approximately 50/50 |
| Valuation quality | Buyer-set, no independent analysis | Limited EBITDA expertise | Variable by vertical | CPA-led, diligence-grade, designed not to re-trade |
| Buyer pool | One buyer | One to two DSOs, small local list | Generic healthcare buyer list | Large premier pool, vetted buyers, poorly run DSOs blacklisted |
| Competitive tension | None | Minimal | Some | Structured auction, multiple offers per listing |
| Transaction rate | Approximately 15% to 20% | Below average | Variable | Consistently high close rate |
7 Questions to Ask Any Broker Before Engagement
- Do you work exclusively on the sell side, or do you also represent buyers? A broker who represents both sides cannot be a true advocate for the seller.
- How many dental practices have you sold, and what is your transaction close rate? Ask for verifiable numbers, not estimates.
- Do you run both doctor-to-doctor and DSO transactions, and can you show me a side-by-side valuation for each path? A single-path broker cannot give you an objective comparison.
- Is your valuation CPA-led and diligence-grade, or is it a free estimate? A defensible valuation can be the foundation of a deal that does not get re-traded.
- How many offers do you typically generate, and how do you create competition among buyers? The answer should describe a structured, multi-buyer process, not a single introduction.
- How do you vet buyers, and have you blacklisted any DSOs for poor post-close performance? Buyer quality can protect your staff, patients, and retained equity.
- Will you defend the agreed valuation through due diligence and closing, or does your involvement end at the letter of intent? Quality-of-earnings defense is often where deals are won or lost after the LOI is signed.
Conclusion & Primary CTA
Selling a premier dental practice is often a once-in-a-career decision. The four-part journey of understanding your options, creating competition, finding the right fit, and maximizing your outcome describes the sequence of decisions that can shape your result. These steps can influence how many offers you receive, whether your valuation holds through due diligence, and how likely you are to close.
Dental practice valuations in 2026 remain near historically high levels, with the specific multiple depending on practice size, profitability, and buyer type. Owners of premier practices who are considering a transition, now or in the next 2 to 3 years, may have a meaningful window to act before market conditions change.
McLerran & Associates has guided thousands of practice owners through this process over roughly 35 years. The firm is sell-side only, dental-only, and runs both exit paths in roughly equal measure. Its CPA-led valuations are designed to hold through diligence, and its competitive process consistently produces multiple offers from vetted buyers.
Discuss your practice, goals, and exit options with McLerran & Associates in a free, confidential consultation. You can also reach the team directly at (512) 900-7989 or info@dentaltransitions.com.
Frequently Asked Questions
Should I sell to a private buyer or a DSO?
The right path can depend on your practice’s size, profitability, and your personal goals after the sale. Smaller premier practices, generally in the $1 million to $1.5 million revenue range, often fit a doctor-to-doctor transaction well, where the buyer is another dentist who takes over clinical care and the seller transitions out over a short period. Larger practices, particularly those generating $1.5 million or more in annual revenue, may be well-suited for a DSO affiliation, where the seller receives a combination of cash, equity in the DSO platform, and possibly an earnout tied to future performance.
Owners in the middle of that range can often pursue either path. The most reliable way to see which serves them better is to model both side by side. Because McLerran & Associates works both markets in roughly equal measure, it can produce a genuine side-by-side valuation that shows what your practice may be worth to a private buyer and to a DSO, so you choose with more complete information.
Why should I pay for a valuation when other firms offer one for free?
A free valuation usually functions as a lead-generation tool, not a full financial analysis. It often produces a number quickly, without the CPA-led add-back work that can make a valuation defensible when a buyer’s due diligence team examines it. When that number cannot be supported, the deal can be renegotiated downward, sometimes significantly.
McLerran & Associates builds its valuations from the ground up by remotely accessing practice management software, cross-referencing data against financials, and unpacking every discretionary, personal, and non-recurring expense to arrive at true profitability. That work is completed before the practice goes to market, so the agreed value has a better chance of holding at closing. In one documented case, a free valuation placed a practice at $2.5 million. McLerran valued it at $4.5 million, and it sold for $5.25 million after a competitive process. The cost of a paid, diligence-grade valuation can be a fraction of the value it protects.
How do I evaluate whether a DSO is a good partner for my practice?
Evaluating a DSO often means treating it like any other investment, because up to 40% of a DSO deal can be paid in equity rather than cash. Key questions include whether the DSO is profitable at the practice level, whether revenue is still growing at offices it already owns, whether the management team has relevant experience, and whether the private equity firm backing it has a track record of successful recapitalizations.
Beyond financials, the post-close environment matters. You can review what the DSO will actually do for your practice in terms of HR, compliance, payroll, IT, and growth support, and what clinical autonomy you will retain. McLerran & Associates vets buyers before they reach the table, blacklisting DSOs known for poor post-close environments, and produces multi-year financial forecasting so you can compare what each finalist’s deal may be worth over time, not just at signing.
Is now a good time to sell a dental practice?
Demand for premier, Class A practices remains strong in 2026, and valuations for well-prepared practices sit near historically high levels. At the same time, several market signals suggest the current window may be narrowing. Some analysts project that EBITDA multiples could compress over the next few years as more practices enter the market and DSOs achieve regional scale, and expiring tax provisions are creating urgency among some sellers to transact before rates change.
The most accurate timing decision usually depends on your specific practice, including its size, profitability, specialty, geography, and readiness for a competitive sale process. McLerran & Associates can provide a candid assessment of where your practice stands today. If you are not ready to sell, the firm can update your valuation at no charge a year later rather than push you into a transaction before the time feels right.
What happens if my practice does not sell?
Close rates can vary dramatically based on how a practice is taken to market. Do-it-yourself sales close at roughly 15% to 20%, which means most unrepresented sellers do not transact. The industry norm for brokered transactions sits around 35% to 40%. McLerran & Associates reports a transaction rate of approximately 85% to 90%, which reflects the combined effect of a defensible valuation, a competitive multi-buyer process, and hands-on advocacy through each stage of the deal.
Deals often fall apart for predictable reasons, such as valuations that cannot survive due diligence, single-bidder exposure with no competitive tension, and the absence of an advisor to help resolve problems as they arise. A well-run process can address all three. If a practice does not transact through McLerran’s process, the firm works to understand why and advises on what operational or financial improvements could strengthen the outcome before re-entering the market.
